Harrow Health, Inc. (HROW)
USD 22.08
(-6.12%)
USD 22.08
(-6.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 311.75 Million USD | 98.54% |
| 2022 | 157.02 Million USD | 59.69% |
| 2021 | 98.32 Million USD | 71.08% |
| 2020 | 57.47 Million USD | -2.73% |
| 2019 | 59.08 Million USD | 19.48% |
| 2018 | 49.45 Million USD | 106.76% |
| 2017 | 23.91 Million USD | -12.22% |
| 2016 | 27.24 Million USD | 92.82% |
| 2015 | 14.13 Million USD | 37.97% |
| 2014 | 10.24 Million USD | -35.02% |
| 2013 | 15.76 Million USD | 47.22% |
| 2012 | 10.7 Million USD | 6551.46% |
| 2011 | 160.95 Thousand USD | -54.31% |
| 2010 | 352.29 Thousand USD | -78.93% |
| 2009 | 1.67 Million USD | -68.66% |
| 2008 | 5.33 Million USD | 25.82% |
| 2007 | 4.24 Million USD | 10516.67% |
| 2006 | 39.94 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 295.06 Million USD | -5.35% |
| 2024 Q2 | 306.17 Million USD | 3.92% |
| 2023 Q3 | 286.06 Million USD | 27.71% |
| 2023 Q1 | 217.49 Million USD | 38.51% |
| 2023 FY | 311.75 Million USD | 98.54% |
| 2023 Q4 | 311.75 Million USD | 8.98% |
| 2023 Q2 | 223.98 Million USD | 2.98% |
| 2022 Q4 | 157.02 Million USD | 58.62% |
| 2022 FY | 157.02 Million USD | 59.69% |
| 2022 Q3 | 98.99 Million USD | 0.95% |
| 2022 Q1 | 97.59 Million USD | -0.75% |
| 2022 Q2 | 98.06 Million USD | 0.48% |
| 2021 Q1 | 56.25 Million USD | -2.13% |
| 2021 FY | 98.32 Million USD | 71.08% |
| 2021 Q2 | 106.96 Million USD | 90.16% |
| 2021 Q3 | 102.8 Million USD | -3.89% |
| 2021 Q4 | 98.32 Million USD | -4.35% |
| 2020 Q1 | 46.89 Million USD | -20.63% |
| 2020 FY | 57.47 Million USD | -2.73% |
| 2020 Q4 | 57.47 Million USD | -3.36% |
| 2020 Q3 | 59.47 Million USD | 20.25% |
| 2020 Q2 | 49.45 Million USD | 5.46% |
| 2019 FY | 59.08 Million USD | 19.48% |
| 2019 Q1 | 66.51 Million USD | 34.5% |
| 2019 Q2 | 65.15 Million USD | -2.03% |
| 2019 Q3 | 54.69 Million USD | -16.05% |
| 2019 Q4 | 59.08 Million USD | 8.02% |
| 2018 Q1 | 21.19 Million USD | -11.36% |
| 2018 Q3 | 28.28 Million USD | 7.45% |
| 2018 Q4 | 49.45 Million USD | 74.81% |
| 2018 FY | 49.45 Million USD | 106.76% |
| 2018 Q2 | 26.32 Million USD | 24.19% |
| 2017 Q2 | 27.59 Million USD | 6.63% |
| 2017 FY | 23.91 Million USD | -12.22% |
| 2017 Q4 | 23.91 Million USD | -8.75% |
| 2017 Q3 | 26.21 Million USD | -5.02% |
| 2017 Q1 | 25.87 Million USD | -5.02% |
| 2016 Q2 | 22.04 Million USD | -12.87% |
| 2016 FY | 27.24 Million USD | 92.82% |
| 2016 Q4 | 27.24 Million USD | 26.63% |
| 2016 Q3 | 21.51 Million USD | -2.41% |
| 2016 Q1 | 25.3 Million USD | 79.08% |
| 2015 Q1 | 9.37 Million USD | -8.47% |
| 2015 Q2 | 16.85 Million USD | 79.78% |
| 2015 Q3 | 15.02 Million USD | -10.88% |
| 2015 Q4 | 14.13 Million USD | -5.93% |
| 2015 FY | 14.13 Million USD | 37.97% |
| 2014 Q2 | 13.87 Million USD | -3.96% |
| 2014 Q3 | 12.4 Million USD | -10.6% |
| 2014 Q4 | 10.24 Million USD | -17.45% |
| 2014 FY | 10.24 Million USD | -35.02% |
| 2014 Q1 | 14.45 Million USD | -8.31% |
| 2013 Q1 | 19.24 Million USD | 79.77% |
| 2013 FY | 15.76 Million USD | 47.22% |
| 2013 Q4 | 15.76 Million USD | -9.43% |
| 2013 Q3 | 17.4 Million USD | -5.3% |
| 2013 Q2 | 18.37 Million USD | -4.52% |
| 2012 Q3 | 11.46 Million USD | 45.2% |
| 2012 Q1 | 224.68 Thousand USD | 39.59% |
| 2012 Q2 | 7.89 Million USD | 3413.79% |
| 2012 Q4 | 10.7 Million USD | -6.61% |
| 2012 FY | 10.7 Million USD | 6551.46% |
| 2011 Q3 | 76.52 Thousand USD | 0.25% |
| 2011 Q2 | 76.33 Thousand USD | -42.61% |
| 2011 Q1 | 133 Thousand USD | -62.25% |
| 2011 FY | 160.95 Thousand USD | -54.31% |
| 2011 Q4 | 160.95 Thousand USD | 110.34% |
| 2010 FY | 352.29 Thousand USD | -78.93% |
| 2010 Q4 | 352.29 Thousand USD | -39.19% |
| 2010 Q3 | 579.37 Thousand USD | -53.35% |
| 2010 Q2 | 1.24 Million USD | 21.99% |
| 2010 Q1 | 1.01 Million USD | -39.11% |
| 2009 Q3 | 2.12 Million USD | -28.57% |
| 2009 FY | 1.67 Million USD | -68.66% |
| 2009 Q2 | 2.97 Million USD | -31.68% |
| 2009 Q4 | 1.67 Million USD | -21.33% |
| 2009 Q1 | 4.35 Million USD | -18.38% |
| 2008 Q4 | 5.33 Million USD | -10.91% |
| 2008 Q2 | 7.18 Million USD | 91.83% |
| 2008 Q3 | 5.98 Million USD | -16.62% |
| 2008 FY | 5.33 Million USD | 25.82% |
| 2008 Q1 | 3.74 Million USD | -11.71% |
| 2007 Q4 | 4.24 Million USD | -15.34% |
| 2007 Q3 | 5 Million USD | 19752.44% |
| 2007 Q1 | 27.41 Thousand USD | -0.08% |
| 2007 Q2 | 25.23 Thousand USD | -7.95% |
| 2007 FY | 4.24 Million USD | 10516.67% |
| 2006 Q3 | 28.46 Thousand USD | 0.0% |
| 2006 FY | 39.94 Thousand USD | 0.0% |
| 2006 Q4 | 27.43 Thousand USD | -3.61% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -370.25% |
| Safety Shot Inc | 12.7 Million USD | -2352.991% |
| Bright Green Corporation | 17.4 Million USD | -1691.382% |
| Embecta Corp. | 1.21 Billion USD | 74.328% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 65.53% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -442.957% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 72.732% |
| Dynavax Technologies Corporation | 997.09 Million USD | 68.734% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -51.487% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 57.194% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 80.198% |
| PainReform Ltd. | 9.93 Million USD | -3039.527% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1039.999% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1039.999% |
| SCYNEXIS, Inc. | 128.41 Million USD | -142.777% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1248.01% |
| Journey Medical Corporation | 76.84 Million USD | -305.672% |
| Alpha Teknova, Inc. | 128.58 Million USD | -142.447% |
| Procaps Group, S.A. | 460.18 Million USD | 32.255% |
| Theratechnologies Inc. | 77.76 Million USD | -300.873% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1993.299% |
| Biofrontera Inc. | 27.93 Million USD | -1016.121% |
| DURECT Corporation | 45.18 Million USD | -589.891% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 77.874% |
| Cronos Group Inc. | 1.13 Billion USD | 72.514% |
| OptiNose, Inc. | 107.72 Million USD | -189.388% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 33.82% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -457.213% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1252.684% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 32.231% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2515.794% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -281.23% |
| Radius Health, Inc. | 1.71 Billion USD | 81.832% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -485.049% |
| ProPhase Labs, Inc. | 91.92 Million USD | -239.133% |
| Phibro Animal Health Corporation | 982.18 Million USD | 68.259% |
| Procaps Group S.A. | 460.18 Million USD | 32.255% |
| Alvotech | 950.09 Million USD | 67.187% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -619.839% |
| Viatris Inc. | 47.68 Billion USD | 99.346% |
| Rockwell Medical, Inc. | 52.17 Million USD | -497.541% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -163.987% |
| SIGA Technologies, Inc. | 254.83 Million USD | -22.335% |
| Tilray Brands, Inc. | 4.33 Billion USD | 92.809% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -13.903% |
| Shineco, Inc. | 84.17 Million USD | -270.346% |
| PetIQ, Inc. | 868.22 Million USD | 64.093% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -3594.563% |
| Incannex Healthcare Limited | 17.04 Million USD | -1728.797% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 90.412% |
| Alimera Sciences, Inc. | 153.52 Million USD | -103.066% |
| Silver Spike Investment Corp. | 88.57 Million USD | -251.962% |
| Assertio Holdings, Inc. | 286.41 Million USD | -8.846% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -5138.052% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -822.467% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -897.84% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2253.305% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -19.389% |
| Hempacco Co., Inc. | 18.04 Million USD | -1627.837% |
| Talphera, Inc. | 20.39 Million USD | -1428.585% |
| Alvotech | 950.09 Million USD | 67.187% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 23.243% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 81.119% |
| Currenc Group, Inc. | 141.49 Million USD | -120.336% |
| Kamada Ltd. | 351.96 Million USD | 11.426% |
| Indivior PLC | 1.95 Billion USD | 84.023% |
| Evoke Pharma, Inc. | 7.06 Million USD | -4310.454% |
| Flora Growth Corp. | 23.62 Million USD | -1219.542% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2253.305% |
| Evolus, Inc. | 188.99 Million USD | -64.951% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 75.64% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 79.394% |
| Akanda Corp. | 8.83 Million USD | -3426.643% |